• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Schizophrenia research and treatment >Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
【24h】

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective

机译：长效注射第二代抗精神病药在第一期精神分裂症治疗中的作用：临床观点

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal data available is limited, many experts recommend prescribing long-acting injectable second-generation antipsychotics (mostly risperidone or alternatively paliperidone) in the early stages of schizophrenia, particularly in patients who have benefited from the original oral molecule in the past and agree to receive long-term injectable treatment. Early application of long-acting injectable second-generation antipsychotics can significantly reduce the risk of relapse in the future and thus improve not only the social and working potential of patients with schizophrenia but also their quality of life.
机译：抗精神病药物治疗后，约有80％的首发精神分裂症患者达到症状缓解。但是，在两年之内，它们中的大多数会复发，主要是由于对疾病的了解程度较低以及对口服药物的不依从性。因此，尽管可用的正式数据有限，但许多专家建议在精神分裂症的早期，特别是在过去从最初的口服分子中受益的患者中，开具长效可注射的第二代抗精神病药（主要是利培酮或帕潘立酮）。并同意接受长期的注射治疗。尽早使用长效注射剂第二代抗精神病药可以显着降低将来复发的风险，从而不仅可以改善精神分裂症患者的社交和工作潜力，而且可以改善他们的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号